Alternative substitutions of N332 in HIV-1AD8 gp120 differentially affect envelope glycoprotein function and viral sensitivity to broadly neutralizing antibodies targeting the V3-glycan

被引:5
作者
Jeffy, Jeffy [1 ]
Parthasarathy, Durgadevi [1 ]
Ahmed, Shamim [1 ]
Cervera-Benet, Hector [1 ]
Xiong, Ulahn [1 ]
Harris, Miranda [1 ]
Mazurov, Dmitriy [1 ]
Pickthorn, Stephanie [1 ]
Herschhorn, Alon [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
机构
[1] Univ Minnesota, Dept Med, Div Infect Dis & Int Med, Minneapolis, MN 55455 USA
[2] Univ Minnesota, Inst Mol Virol, Minneapolis, MN 55455 USA
[3] Univ Minnesota, Inst Engn Med, Minneapolis, MN 55455 USA
[4] Univ Minnesota, Ctr Genom Engn, Minneapolis, MN 55455 USA
[5] Univ Minnesota, Microbiol Immunol & Canc Biol Grad Program, Minneapolis, MN 55455 USA
[6] Univ Minnesota, Coll Vet Med, Grad Program, Minneapolis, MN 55455 USA
[7] Univ Minnesota, Mol Pharmacol & Therapeut Grad Program, Minneapolis, MN 55455 USA
基金
美国国家卫生研究院;
关键词
human immunodeficiency virus; broadly neutralizing antibodies; V3-glycan; fitness; POTENT NEUTRALIZATION; REVERSE-TRANSCRIPTASE; COMMON FEATURES; HIV; IDENTIFICATION; GLYCOSYLATION; INHIBITORS; RECEPTOR; COMPLEX; DESIGN;
D O I
10.1128/mbio.02686-23
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The envelope glycoprotein (Env) trimer on the surface of human immunodeficiency virus type I (HIV-1) mediates viral entry into host CD4(+) T cells and is the sole target of neutralizing antibodies. Broadly neutralizing antibodies (bnAbs) that target gp120 V3-glycan of HIV-1 Env trimer are potent and block the entry of diverse HIV-1 strains. Most V3-glycan bnAbs interact, to a different extent, with a glycan attached to N332, but Asn at this position is not absolutely conserved or required for HIV-1 entry based on the prevalence of N332 in different circulating HIV-1 strains from diverse clades. Here, we studied the effects of amino acid changes at position 332 of HIV-1(AD8) Envs on HIV-1 sensitivity to antibodies, cold exposure, and soluble CD4. We further investigated how these changes affect Env function and HIV-1 infectivity in vitro. Our results suggest robust tolerability of HIV-1(AD8) Env N332 to changes, with specific changes that resulted in extended exposure of gp120 V3 loop, which is typically concealed in most primary HIV-1 isolates. Viral evolution leading to Asn at position 332 of HIVAD8 Envs is supported by the selection advantage of high levels of cell-cell fusion, transmission, and infectivity with high levels of cell surface expression and slightly higher gp120 shedding than most N332 variants. Thus, tolerance of HIV-1(AD8) Envs to different amino acids at position 332 provides increased flexibility to respond to changing conditions/environments and evade the immune system. Modeling studies of the distance between N332 glycan and specific bnAbs were in agreement with N332 glycan dependency on bnAb neutralization. Overall, our studies provide insights into the contribution of specific amino acids at position 332 to Env antigenicity, stability on ice, and conformational states. IMPORTANCE Glycan attached to amino acid asparagine at position 332 of HIV-1 envelope glycoproteins is a main target of a subset of broadly neutralizing antibodies that block HIV-1 infection. Here, we defined the contribution of different amino acids at this position to Env antigenicity, stability on ice, and conformational states.
引用
收藏
页数:19
相关论文
共 62 条
[1]   Precursor Frequency and Affinity Determine B Cell Competitive Fitness in Germinal Centers, Tested with Germline-Targeting HIV Vaccine Immunogens [J].
Abbott, Robert K. ;
Lee, Jeong Hyun ;
Menis, Sergey ;
Skog, Patrick ;
Rossi, Meghan ;
Ota, Takayuki ;
Kulp, Daniel W. ;
Bhullar, Deepika ;
Kalyuzhniy, Oleksandr ;
Havenar-Daughton, Colin ;
Schief, William R. ;
Nemazee, David ;
Crotty, Shane .
IMMUNITY, 2018, 48 (01) :133-+
[2]  
Ahlers JD, 2014, DISCOV MED, V17, P187
[3]   Enhancing anti-viral neutralization response to immunization with HIV-1 envelope glycoprotein immunogens [J].
Ahmed, Shamim ;
Parthasarathy, Durgadevi ;
Newhall, Rachael ;
Picard, Tashina ;
Aback, Morgainne ;
Ratnapriya, Sneha ;
Arndt, William ;
Vega-Rodriguez, Widaliz ;
Kirk, Natalie M. ;
Liang, Yuying ;
Herschhorn, Alon .
NPJ VACCINES, 2023, 8 (01)
[4]   Identification of Common Features in Prototype Broadly Neutralizing Antibodies to HIV Envelope V2 Apex to Facilitate Vaccine Design [J].
Andrabi, Raiees ;
Voss, James E. ;
Liang, Chi-Hui ;
Briney, Bryan ;
Mccoy, Laura E. ;
Wu, Chung-Yi ;
Wong, Chi-Huey ;
Poignard, Pascal ;
Burton, Dennis R. .
IMMUNITY, 2015, 43 (05) :959-973
[5]   Effect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption [J].
Bar, K. J. ;
Sneller, M. C. ;
Harrison, L. J. ;
Justement, J. S. ;
Overton, E. T. ;
Petrone, M. E. ;
Salantes, D. B. ;
Seamon, C. A. ;
Scheinfeld, B. ;
Kwan, R. W. ;
Learn, G. H. ;
Proschan, M. A. ;
Kreider, E. F. ;
Blazkova, J. ;
Bardsley, M. ;
Refsland, E. W. ;
Messer, M. ;
Clarridge, K. E. ;
Tustin, N. B. ;
Madden, P. J. ;
Oden, K. S. ;
O'Dell, S. J. ;
Jarocki, B. ;
Shiakolas, A. R. ;
Tressler, R. L. ;
Doria-Rose, N. A. ;
Bailer, R. T. ;
Ledgerwood, J. E. ;
Capparelli, E. V. ;
Lynch, R. M. ;
Graham, B. S. ;
Moir, S. ;
Koup, R. A. ;
Mascola, J. R. ;
Hoxie, J. A. ;
Fauci, A. S. ;
Tebas, P. ;
Chun, T-W .
NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (21) :2037-2050
[6]   Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals [J].
Bar-On, Yotam ;
Gruell, Henning ;
Schoofs, Till ;
Pai, Joy A. ;
Nogueira, Lilian ;
Butler, Allison L. ;
Millard, Katrina ;
Lehmann, Clara ;
Suarez, Isabelle ;
Oliveira, Thiago Y. ;
Karagounis, Theodora ;
Cohen, Yehuda Z. ;
Wyen, Christoph ;
Scholten, Stefan ;
Handl, Lisa ;
Belblidia, Shiraz ;
Dizon, Juan P. ;
Vehreschild, Joerg J. ;
Witmer-Pack, Maggi ;
Shimeliovich, Irina ;
Jain, Kanika ;
Fiddike, Kerstin ;
Seaton, Kelly E. ;
Yates, Nicole L. ;
Horowitz, Jill ;
Gulick, Roy M. ;
Pfeifer, Nico ;
Tomaras, Georgia D. ;
Seaman, Michael S. ;
Faetkenheuer, Gerd ;
Caskey, Marina ;
Klein, Florian ;
Nussenzweig, Michel C. .
NATURE MEDICINE, 2018, 24 (11) :1701-+
[7]   Structural principles controlling HIV envelope glycosylation [J].
Behrens, Anna-Janina ;
Crispin, Max .
CURRENT OPINION IN STRUCTURAL BIOLOGY, 2017, 44 :125-133
[8]   MiRNA-103 downmodulates CCR5 expression reducing human immunodeficiency virus type-1 entry and impacting latency establishment in CD4+ T cells [J].
Bellini, Nicolas ;
Lodge, Robert ;
Pham, Tram N. Q. ;
Jain, Jaspreet ;
Murooka, Thomas T. ;
Herschhorn, Alon ;
Bernard, Nicole F. ;
Routy, Jean-Pierre ;
Tremblay, Cecile L. ;
Cohen, Eric A. .
ISCIENCE, 2022, 25 (10)
[9]   Multiple Origins of Virus Persistence during Natural Control of HIV Infection [J].
Boritz, Eli A. ;
Darko, Samuel ;
Swaszek, Luke ;
Wolf, Gideon ;
Wells, David ;
Wu, Xiaolin ;
Henry, Amy R. ;
Laboune, Farida ;
Hu, Jianfei ;
Ambrozak, David ;
Hughes, Marybeth S. ;
Hoh, Rebecca ;
Casazza, Joseph P. ;
Vostal, Alexander ;
Bunis, Daniel ;
Nganou-Makamdop, Krystelle ;
Lee, James S. ;
Migueles, Stephen A. ;
Koup, Richard A. ;
Connors, Mark ;
Moir, Susan ;
Schacker, Timothy ;
Maldarelli, Frank ;
Hughes, Stephen H. ;
Deeks, Steven G. ;
Douek, Daniel C. .
CELL, 2016, 166 (04) :1004-1015
[10]   HIV-1 Neutralizing Antibody Signatures and Application to Epitope-Targeted Vaccine Design [J].
Bricault, Christine A. ;
Yusim, Karina ;
Seaman, Michael S. ;
Yoon, Hyejin ;
Theiler, James ;
Giorgi, Elena E. ;
Wagh, Kshitij ;
Theiler, Maxwell ;
Hraber, Peter ;
Macke, Jennifer P. ;
Kreider, Edward F. ;
Learn, Gerald H. ;
Hahn, Beatrice H. ;
Scheid, Johannes F. ;
Kovacs, James M. ;
Shields, Jennifer L. ;
Lavine, Christy L. ;
Ghantous, Fadi ;
Rist, Michael ;
Bayne, Madeleine G. ;
Neubauer, George H. ;
McMahan, Katherine ;
Peng, Hanqin ;
Cheneau, Coraline ;
Jones, Jennifer J. ;
Zeng, Jie ;
Ochsenbauer, Christina ;
Nkolola, Joseph P. ;
Stephenson, Kathryn E. ;
Chen, Bing ;
Gnanakaran, S. ;
Bonsignori, Mattia ;
Williams, LaTonya D. ;
Haynes, Barton F. ;
Doria-Rose, Nicole ;
Mascola, John R. ;
Montefiori, David C. ;
Barouch, Dan H. ;
Korber, Bette .
CELL HOST & MICROBE, 2019, 25 (01) :59-+